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Eighty-four women at high risk for ovarian cancer by having first-degree relatives with
epithelial ovarian cancer participated in a newly established, early ovarian cancer detection
program at Yale University. Participants were to be evaluated with physical examinations and
circulating tumor markers at entry and every six months thereafter. Endovaginal ultrasound
and color Doppler flow studies were to be performed at three and nine months following entry
into the program. In addition, women were encouraged to follow American Cancer Society
guidelines for mammography. Stool was checked for occult blood. Endometrial sampling was
offered to post-menopausal women. No participant has developed an ovarian cancer since
entering the program. One woman has been diagnosed to have breast cancer. False-positive
levels of circulating tumor markers (CA 125, 4/84 [4.8 percent]; lipid-associated sialic acid in
plasma, 13/84 [15.5 percent]; NB/70K, 4/84 [4.8 percent]; and urinary gonadotropin fragment,
1/65 [1.5 percent]) were observed on entry into the program. Low resistive indices (<0.5) were
documented in 8/91 (8.8 percent) ovaries studied by the color Doppler flow technique. One
participant underwent a laparotomy based on a false-positive endovaginal ultrasound examina-
tion. Tests now being employed in community practice have a high likelihood of being
associated with false-positive results. Therapeutic interventions based on isolated abnormal
tumor markers or ultrasound studies obtained from women with family histories of ovarian
cancer may lead toinappropriate surgery. It is necessary for cancer centers to develop expertise
in ovarian cancer detection techniques to advise physicians in their geographic areas appropri-
ately about the significance ofthe abnormal screening test.
INTRODUCTION
A program for the early detection of ovarian cancer in a population ofwomen at
increased risk for the disease has been established at Yale University School of
Medicine. The background and rationale for this program is presented in the
preceding article [1]. The specific aims ofthis program are (1) to evaluate a panel of
tumor markers and endovaginal ultrasound techniques in women at increased risk
for ovarian cancer byvirtue ofhaving a first-degree relative (mother, sister) who has
had an epithelial ovarian cancer in order to identifywhich women may actually have
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early-stage ovarian cancer, (2) to monitor thevalue ofcirculating tumormarkers and
endovaginal ultrasound studies in order to establish how often these fail by giving
false-positive results in the absence ofcancer and the clinical strategies to assess the
cause ofthese failures, and (3) to identify individuals at high risk for ovarian cancer
who may benefit from prophylactic oophorectomy by assessing their personal histo-
ries, including medical, nutritional, and personal hygiene habits, their family histo-
ries, the levels of circulating tumor markers, the results of endovaginal ultrasound
studies and cytogenetic studies. As this program has been active for less than one
year, the results presented represent extremely preliminary data.
MATERIALS AND METHODS
The Yale Ovarian Cancer Detection Program began onAugust 1, 1990. Adetailed
description of the program is presented in the preceding article [1]. Eighty-four
women have completed a family and medical history form and undergone an
assessment by a socialworker, aphysical examination (including pelvic examination)
by a gynecologic oncologist, and have had blood and urine obtained for tumor
markers and cytogenetic studies. Most have undergone at least one endovaginal
ultrasound study, which is performed at three and nine months following entry into
the program. Physical examinations and tumor marker studies are performed on
entry into the study and at six and 12 months following entry. The time interval for
subsequent examinationswillbe determined afteranalyzingthefirstyearofthe study
results. It is anticipated that these examinations will be conducted at less frequent
intervals in subsequent programyears.
All women entering into the study had blood analyzed for the circulating tumor
markers CA 125, lipid-associated sialic acid in plasma (LSA), and NB/70K [2-4].
Sixty-five women had urine assayed for urinary gonadotropin fragment (UGF)1 [5].
In addition, blood specimens have been stored for subsequent assays for colony
stimulating factor 1 (macrophage colony stimulating factor) [6]. All assays presented
were performed by Dianon Systems, Inc, a reference laboratory in Stratford,
Connecticut. CA 125 assays were performed using a kit from Centocor, Inc.,
Malvern, Pennsylvania; LSA was assayed using a modification of the technique
described by Katopodis et al. [7]; NB/70K was assayed using the method of Knauf
[8]. UGF was assayed using kits provided by Triton Diagnostics, Inc. Alameda,
California.
Endovaginal ultrasound examination isperformed toexamine themorphology and
vascularity of the ovaries. Endovaginal ultrasound color flow transducers are avail-
able on twoATL9s. Askilled research sonographer andfive experienced radiologists
dedicated to ultrasound imagingperform and interpret the examinations.
All participants are requested to follow the American Cancer Society guidelines
for mammography screening. Pap smears are offered to those women not routinely
having Pap smears or those requesting that one be performed. Participants routinely
have stool checked for the presence of occult blood. Post-menopausal women are
offered the option of endometrial sampling performed to rule out the presence of
occult endometrial cancer.
'UGF is nowcommercially available, called UGP (urinarygonadotropin peptide).
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TABLE 1
Participants' Characteristics
No. Patients
Age (Years)
<35 10
35-39 22
40-44 24
45-49 5
50-54 8
55-59 5
60-64 5
65-69 3
70+ 2
Race
White 82
Black 1
South Asian 1
Blood Type (by History)
0 12
A 7
B 2
AB 4
Religion
Protestant 34
Catholic 27
Jewish 20
Russian Orthodox 1
None 2
History ofMumps
Yes 49
No 28
Uncertain 7
Talc UseforPersonalHygiene
Yes 45
No 38
Uncertain 1
Tobacco Usea
Yes 40
No 44
Alcohol Use
Yes 76
No 7
No Response 1
aDefined as ever or never used.
RESULT
Participant characteristics are presented in Table 1; only 25 women knew their
blood types. Their menstrual and reproductive histories are presented in Table 2.
The participants' family history for breast, endometrial, colon, and rectal cancer is
shown in Table 3. Seventy-one women had a mother as the first-degree relative with
ovarian cancer, nine had a sister, two had a mother and a sister, and two had aSCHWARTZ ET AL.
TABLE 2
Menstrual and Reproductive History
No.
Patients
Menarche (Years)
9 1
10 4
11 9
12 25
13 21
14 8
15 5
16 6
17 1
18 1
Unknown 3
CurrentMenstrual Status
Menstruating 62
Post-Menopausal (spontaneous) 17
Surgical Menopause 4
Pharmacologic Menopause 1
Gravidity
0 14
1 11
2 20
3 15
4 12
5 8
6 2
7 0
8 2
Breast-Fed Children
0 16
1 8
2 11
3+ 11
Non-Applicable 16
mother and a maternal grandmother. The participants' contraceptive history is
summarized in Table 4.
To date, none ofthe participants in this early detection program has developed a
carcinoma ofthe ovary. Threewomen have, however, undergone laparotomiesbased
on physical findings or laboratory test results. Their histories are briefly summarized
as follows:
A41-year-old nulligravida, whosemother and maternal aunthad each had ovarian
cancer, had been having routine semiannual pelvic examinations, by a gynecologist,
that were reported to be normal. At the initial physical examination on entry to the
screeningprogram, shewasfound to have a 2cmirregularnodule alongtheright side
of the uterine corpus. Her initial CA 125 was 27 U/mL, LSA was 21.6 mg/dl,
NB/70K was 0, and UGF was 4.1 fm/mg creatinine. She was referred back to her
gynecologist, who then confirmed the presence of bilateral adnexal masses by
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TABLE 3
Family Cancer History
Colon-
Relationship Breast Endometrial Rectal
Self 3
Matemal
Mother 6 1 1
Sister 5 1
Aunt 14 2 3
Grandmother 4 2
Cousin 2
Great Grandmother 1 2
Uncle 4
Grandfather _ 2
Total 32 3 15
Patemal
Aunt 11 1 3
Grandmother 4
Uncle 2
Grandfather _ 1
Total 15 1 6
ultrasound examination. She underwent a total abdominal hysterectomy and bilat-
eral salpingo-oophorectomy forwhat proved to be bilateral ovarian endometriomas.
A 40-year-old gravida 2, para 0, abortions 2, whose mother and grandmother had
each succumbed to ovarian cancer, was found to have an abnormal Pap smear (CIN
2-3). She had been followed approximately every six months with pelvic examina-
TABLE 4
Contraceptive History'
Contraceptive Techniques
Oral
Usage Years Contraceptives Diaphragm Condoms Rhythm IUD
None 29 47 52 78 65
<1 7 2 1
1 5 2 5 1 2
2 3 4 2
3 3 4 3 2 1
4 5 4 1 3
5 6 2 2 1 1
6-10 15 3 4 2 8
11-15 3 3 2 - 1
15+ 4 7 2 1
Unable to
quantify years 3 9 12 2 1
'Additional forms of contraception: Bilateral tubal ligations, 4; contraceptive
foam, 2; husband hadvasectomy, 2; contraceptive sponge, 2;withdrawal, 1
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tions and Pap smears, all of which had been reported to be normal, including her
most recent Pap smear, obtained four months prior to joining the ovarian cancer
detection program. Her initial CA 125 was 11 U/mL, LSA was 16.8 mg/dl, and
NB/70K was 0. She was referred back to her gynecologist, who confirmed the
presence ofcarcinoma in situ, involving the exocervix and endocervix. She electively
underwent a total abdominal hysterectomy, bilateral salpingo-oophorectomy, omen-
tectomy, and lymph node sampling (the latter two procedures as part ofour surgical
staging for possible occult ovarian cancer). No occult cancerwas identified.
A42-year-old nulligravida,whose mother and maternal aunt had each had ovarian
cancer, was known to have a multilobulated fibroid uterus. Initial physical examina-
tion confirmed the presence of uterine leiomyomata. Serum tumor markers were
normal (CA 125 was 18 U/mL, LSAwas 11 mg/dl, NB/70Kwas 0, and UGFwas 0.7
fm/mgcreatinine). Endovaginal ultrasound studies three months later revealed a 4.5
by4.9 by4.2 cm right ovarian cystwith internal echoes, a resistive indexof0.62, and a
small amount of free fluid in the cul-de-sac. A follow-up endovaginal ultrasound
revealed the cyst to contain solid elements not previously observed, and the fluid in
the cul-de-sac had increased. The peak systolic blood flow was noted to be at the
level of the systemic circulation. These findings were viewed as compatible with
ovarian cancer. Surgerywas recommended. The findings at laparotomyrevealed that
the right ovarywasnormal, and the imaged masswas a right-sided subserosal uterine
leiomyoma.
Four participants had elevated values of CA 125 to 38, 40, 50, and 57 U/mL, the
normal value being less than 35 U/mL (Table 5). Three appeared to be secondary to
endometriosis, and one preceded by two months the appearance ofabenign ovarian
cyst. Thirteen participants had elevations ofLSA greater than 24 mg/dl, but in each
case the CA 125 was normal. Therefore, they are staying in the diagnostic routine
established for the first year of the program. Four subjects have had mild elevations
of NB/70K to 39, 42, 44, and 506 U/mL, the normal cut-offbeing 35 U/mL. All of
these were associated with LSA greater than 24 mg/dL and normal CA 125 assays,
suggesting that the participants might be suffering from inapparent infections rather
than an occult malignancy. These participants are remaining in the diagnostic
routine established for the first year of the program. One of 65 participants had an
elevated UGF (5.1 fm/mgcreatinine, the normal cut-offbeing less than 5 fm/mg).
To date, 91 ovaries have been visualized by endovaginal ultrasound and color
Doppler flow studies performed. Eight ovaries (8.8 percent) were associated with a
resistive index of less than 0.5, none ofwhich have been associated with an ovarian
malignancy (Table 5). These patients continue to be followed on protocol, as none
had elevated CA 125 assays (Table 5). In general, repeat color Doppler flow studies
have been consistentwith the initial studies. The participantwith the lowest resistive
index, 0.41, has just been reported to have a CA 125 elevation to 88 U/mL. She is
currentlyundergoing additional evaluation.
One participant has been found to have an abnormal mammogram change, biopsy
ofwhich proved to be breast cancer. That patient has now undergone a mastectomy
and primarybreast reconstruction. She is one offour patients (Table 5) who initially
had an elevated LSA (30.9 mg/dl) and NB/70K (39 U/mL); however, her tumor
marker studies were repeated ten days prior to surgery and all were within normal
limits (LSA, 22.2 mg/dl; NB/70K, 12 U/mL; CA 125, 22 U/mL). Five women were
found to have occult blood in their stool, and all were sent to their internists for
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TABLE 5
Abnormal Imaging and Tumor Marker Assays
Resistive Index
Right Left CA 125 LSA NB/70K UGF
Patient No. Ovary Ovary (U/mL) (mg/dl) (U/mL) (fm/mg)
N/I
0.53
0.75
0.50
CA 125 (Elevated)
N/A 38
1.0 50
0.55 57
LSOb 40
UGF (Elevated)
- 15
1.0
RSOc4
1.0
1.0
1.0
1.0
1.0
23.1
19.4
18.6
21.0
15.2
LSA, NB/7OKElevated
1.0 4 24.7
0.57 16 30.9
14 24.7
1.0 30 24.2
- 5 25.4
1.0 17 34.3
- 24 24.2
0.67 5 27.7
16 27.2
0.63 10 25.2
1.0 13 24.4
10 30.3
13 24.5
LowResistive Index
016 1.0 0.49 9 21.7
025 1.0 0.47 9 14.5
054 1.0 0.46 9 23.0
056 0.46 0.41 3 19.0
060 0.45 0.78 11 15.6
062 0.44 LSO 21 20.4
081 0.41 1.00 33 18.8
'N/A, Not Available
bLSO, Status post-left salpingo-oophorectomy
CRSO, Status post-right salpingo-oophorectomy
dPatient subsequently diagnosed to have breast cancer
0 4.7
0
24 0.2
5 0.7
0 5.1
12 2.5
39 1.1
15
31
24 2.8
42
5 0.2
44 0.9
18
506 2.1
14 0.6
0 0.1
16 0.9
3 1.4
0 1.0
11 0.2
17 0
1
32 0.2
0 0
further evaluation. Each occurrence of occult blood in the stool proved to be
unrelated to cancer: four were associated with the presence ofhemorrhoids and one
with recent dental surgery.
A number of findings were either unanticipated or incompletely prepared for,
prior to initiating the early detection program. These findings were related to
emotional events the participants experienced at having had a mother or sister with
ovarian cancer. Ourpsychological profile ofthe participants suggested that none had
resolved the deaths of their mothers. Interestingly, sisters often had strikingly
different views of the nature of their mother's illness. In addition, participants
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responded poorly when told that very minor abnormalities of no particular clinical
significance were observed on endovaginal ultrasound examinations. The women
who had such changes were usually invited to return in a month for reassessment.
Despitebeing assured that this innovation was achange probably reflecting sophisti-
cated new technology rather than suggesting an occult malignancy, at least three
patients went from the diagnostic imaging suite to their gynecologists' offices and
demandedprompt examinations, as theywere certain they had ovarian cancer.
The latter findings required a response. To this end, participants are now better
informed about the ultrasound examinations and the possibilities of identifying
abnormal changes that almost certainly are of no particular consequence. They are
made aware ofthis factprior toundergoing the ultrasound examinations. (A similar
policyregardingfalse-positive circulating tumor markers had already been in place.)
Participants are informed in advance that, should a small ovarian cyst be identified,
theymay be asked to take oral contraceptives for one to two cycles to see if the cyst
may be suppressed. In addition, our nurses and social workers have been invited to
observe endovaginal ultrasound examinations so that they can be more consistent in
describing the ultrasound examinations when they interview program participants.
Finally, a bimonthly multidisciplinary ultrasound conference has been instituted to
review any abnormalities found on endovaginal ultrasound studies in order to be
certain that a consistent approach to patient care is practiced for all women
participating in this study.
CONCLUSIONS
The existence ofthisprogram foronlyeight months makes drawing any significant
conclusions difficult; however, many important observations have been made in a
population ofwomen at high risk for ovarian cancer.
The first observation was the intense interest expressed by women who had a
mother or sister who had experienced ovarian cancer. We received modest local
newspaperconverage and local television and radio publicity, yet within a few weeks
received more than 1,000phone calls ofinquiry, and identified 285 women who were
appropriate for the program. The failure to enter more women into the program is
predominantly due to the initial costs, which had to be borne in part by the
participants. We have steadily reduced financial charges and have submitted grant
applications in an effort to eliminate all financial charges. Women who are unable to
pay the costs of this study are accepted without financial obligation.
The second observationwas 61 ofthe 84(72.6percent) women participating in this
study were under the age of 50years. While the population participating may seem
young, the mean age for women with familial ovarian cancer is 47.7 years, as
compared to 59 years for the general population [9,10]. In addition, there is a
tendency for women experiencing familial ovarian cancer overwhelmingly to have
histologically poorly differentiated serous carcinomas. These malignancies spread
rapidly. Successful management requires early recognition. The population studied
seems to be appropriate to accomplish our goals.
The third observation related to the emotional fragility women demonstrated
when interviewed by an experienced, oncologically oriented medical social worker
about their family cancer history. Many women still had unresolved issues of grief
and loss. Anon-neurotic sense ofgriefandlosswasdemonstrated. These issueswere
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not discussed by patients in a clinical sense, nor did these feelings inhibit daily
functioning, but their feelings of loss were very evident in their reminiscences.
Women were given an opportunity to discuss their concerns about ovarian cancer
and the disruption it created within the family system. Most of the women in the
studyhad never had the opportunity to discuss theirgriefand loss andwelcomed this
chance to express emotions and concerns. In many instances, the normal feelings of
loss, disruption, and griefwere the factors which motivated the women to enter the
study. The clinic offers anopportunity for emotional catharsis and also allowswomen
to make intelligent, informed decisions about preventive health care. They are
enabled to access health care servicesvia an early detection clinicfor ovarian cancer.
Moreover, differences in perception regarding their mother's illness were striking
among siblings. The latter observation will be the subject ofa subsequent report.
Of great concern was the acute anxiety reaction many participants demonstrated
when told they had mildly abnormal tests or changes on ultrasound evaluations,
using highly sophisticated technology. The anxiety exhibited by the women in this
study highlights the need for more intense preparation of the patients. Orientation
and education before the initial tests must be increased, and the need for follow-up
by staff members at the time of the tests would address the women's anxiety. The
anxiety exhibited the intense fear about ovarian cancer and eachwoman's desperate
desire to avail herselfofthe best medical care possible.
The most important clinical observation regarding ovarian cancer detection was
the lack of specificity for all of the early detection techniques used. CA 125, the
standard tumor marker most often used for monitoring women known to have
ovarian cancer, was elevated above a cut-off of 35 U/mL in four of 84 (4.8 percent)
women on entry to the program; LSA was elevated above 24 mg/dl in 13 of84 (15.5
percent), and NB/70K was elevated above 35 U/mL in 4 of 84 (4.8 percent) of
participants. Only one of 65 participants had an elevated value of UGF above 5.0
fm/mg creatinine. UGF was below 5 fm/mg creatinine in three of the four women
who had elevations of CA 125 greater than 35 U/mL and in nine patients assayed
who had elevated LSA and NB/70K. Endovaginal ultrasound studies were associ-
ated with resistive indices ofless than 0.5 in eight of91 (8.8 percent) ovaries studied.
Furthermore, one woman was thought to have morphologic ultrasound features
compatible with an epithelial ovarian cancer and underwent surgery for this false-
positive finding.
Thus, tests which are now being routinely employed by physicians in community
practice have a high likelihood of being associated with false-positive results. The
preliminary results of this study confirm that therapeutic interventions based on
isolated abnormal tumor marker levels orultrasound examinations fromwomen with
family histories of ovarian cancer may lead to inappropriate surgery. It is extremely
important to continue accruing women to this study, to evaluate new screening
techniques, and to establish similar programs around the United States. It is
necessary for clinical cancer centers to develop expertise in detection techniques to
advise physicians in their geographic areas appropriately about the significance of
the abnormal screening test.
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